Moderna has dozens of mRNA "vaccines" in their development pipeline:

mRNA-1010 (Flu) CLINICAL TRIAL NCT05606965

mRNA-1011 (Flu) CLINICAL TRIAL NCT05827068

mRNA-1012 (Flu) CLINICAL TRIAL NCT05827068

mRNA-1018 (Pandemic Flu) CLINICAL TRIAL NCT05972174

mRNA-1020 (Flu) CLINICAL TRIAL NCT05333289

mRNA-1030 (Flu) CLINICAL TRIAL NCT05333289

mRNA-1045 (Flu + RSV vaccine) CLINICAL TRIAL NCT05585632

MRNA-1073 (COVID + FLU) CLINICAL TRIAL NCT05375838

mRNA-1083 (Flu + COVID vaccine) CLINICAL TRIAL NCT06694389

mRNA-1189 (EBV vaccine to prevent infectious mononucleosis) CLINICAL TRIAL NCT05164094

mRNA 1195 (EBV vaccine to address EBV sequelae) CLINICAL TRIAL NCT05831111

mRNA-1215 (Nipah vaccine) CLINICAL TRIAL NCT05398796

mRNA-1230 (Flu + COVID + RSV vaccine) CLINICAL TRIAL NCT05585632

mRNA-1273 (COVID-19 vaccine Spikevax®)

mRNA-1273.815 (COVID-19 vaccine adolescents)

mRNA-1273.815 (COVID-19 vaccine pediatrics)

mRNA-1287 (Endemic HCoV Human Coronavirus vaccine)

mRNA-1283 (COVID-19 vaccine Next gen) CLINICAL TRIAL NCT05137236

mRNA-1345 (RSV mRESVIA® Respiratory syncytial virus vaccine older adults)

mRNA-1345 (RSV Respiratory syncytial virus vaccine pediatrics) CLINICAL TRIAL NCT06143046

mRNA-1365 (RSV + hMPV Human MetaPneumoVirus vaccine) CLINICAL TRIAL NCT05743881

mRNA-1403 (Norovirus vaccine) CLINICAL TRIAL NCT06592794

mRNA-1405 (Norovirus vaccine) CLINICAL TRIAL NCT05992935

mRNA-1468 (VZV Varicella-zoster virus chickenpox/shingles vaccine) CLINICAL TRIAL NCT05701800

mRNA-1574 (HIV vaccine)

mRNA-1608 (HSV Herpes Simplex Virus vaccine) CLINICAL TRIAL NCT06033261

mRNA-1644 (HIV Vaccine) CLINICAL TRIAL NCT05001373

mRNA-1647 (Cytomegalovirus (CMV) vaccine) CLINICAL TRIAL NCT05085366

mRNA-1769 (Mpox vaccine) CLINICAL TRIAL NCT05995275

mRNA-1893 (Zika vaccine) CLINICAL TRIAL NCT04917861

mRNA-1975 (Lyme Vaccine) CLINICAL TRIAL NCT05975099

mRNA-1982 (Lyme Vaccine) CLINICAL TRIAL NCT05975099

CANCER THERAPIES:

mRNA-2752 (OX40L/IL-23/IL-36γ (Triplet) Solid tumors/lymphoma) CLINICAL TRIAL NCT03739931

mRNA-4157 (Individualized neoantigen therapy (INT) adjuvant melanoma)

mRNA-4157 (Individualized neoantigen therapy (INT) – adjuvant NSCLC)

mRNA-4157 (Individualized neoantigen therapy (INT) – adjuvant NSCLC post neoadjuvant treatment)

mRNA-4157 (Individualized neoantigen therapy (INT) – cutaneous squamous cell carcinoma (cSCC))

mRNA-4157 (Individualized neoantigen therapy (INT) – renal cell carcinoma (RCC))

mRNA-4157 (Individualized neoantigen therapy (INT) - adjuvant non-small cell lung cancer (NSCLC))

mRNA-4157 (Individualized neoantigen therapy (INT) – early and late solid tumor (first in human)) CLINICAL TRIAL NCT03313778

mRNA-4157 (Individualized neoantigen therapy (INT) – renal cell carcinoma (RCC))

mRNA-4157 (Individualized neoantigen therapy (INT) – bladder cancer)

mRNA-4359 (Checkpoint vaccine) CLINICAL TRIAL NCT05533697

mRNA-5671 (KRAS vaccine) CLINICAL TRIAL NCT03948763